<DOC>
	<DOCNO>NCT03016169</DOCNO>
	<brief_summary>The objective study evaluate safety performance Trifecta™ GT ( Glide Technology ) valve 5 year follow-up prospective , multi-center , real-world setting . This study intend satisfy post-market clinical follow-up requirement CE Mark Europe .</brief_summary>
	<brief_title>Trifecta™ GT Post Market Clinical Follow-up</brief_title>
	<detailed_description>The study prospective multi-center evaluation approximately 350 subject implanted St. Jude Medical ( SJM ) Trifecta™ GT valve . It conduct approximately 35 site worldwide . Subjects follow 5 year . The total duration study expect 6 year , assume subject enrol within 1 year study initiation . To ensure enrollment balance across site , individual site enroll 10 % sample size ( n=35 subject ) without prior approval sponsor .</detailed_description>
	<criteria>1 . Subject candidate surgical aortic valve replacement per current guideline intend implanted St. Jude Medical Trifecta GT valve . 2 . Subject legal age country subject enrol . 3 . Subject must willing able provide write informed consent participate study . 4 . Subject must willing able comply followup requirement . 1 . Subject undergoes concomitant procedure mitral tricuspid valve replacement time Trifecta GT valve implantation surgery . 2 . Subject contraindication cardiac surgery . 3 . Subject pregnant . Pregnancy assess subject informing physician . 4 . Subject active endocarditis ( subject previously experience endocarditis must two document negative blood culture result antibiotic therapy prior valve implantation surgery ) . 5 . Subject stroke transient ischemic attack within 6 month prior plan valve implantation surgery . 6 . Subject undergoing renal dialysis . 7 . Subject history active drug addiction , active alcohol abuse , psychiatric hospital admission psychosis within prior 2 year . 8 . Subject document thrombus leave atrium leave ventricle time valve implantation surgery . 9 . Subject leave ventricular ejection fraction &lt; 30 % . 10 . Subject previously enrol Trifecta GT PMCF study withdrawn ( subject enrol twice study ) . 11 . Preoperative evaluation indicate significant cardiovascular abnormality aortic dissection ventricular aneurysm . 12 . Subject life expectancy le 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>